var data={"title":"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/contributors\" class=\"contributor contributor_credentials\">Angela Sun, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/contributors\" class=\"contributor contributor_credentials\">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/contributors\" class=\"contributor contributor_credentials\">Elizabeth TePas, MD, MS</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 23, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Glucose-6-phosphatase deficiency (G6PD, MIM #232200), also known as von Gierke disease, is a glycogen storage disease (GSD). It was the first GSD to have the responsible enzyme defect identified and therefore is designated GSD I (<a href=\"image.htm?imageKey=PEDS%2F54417\" class=\"graphic graphic_table graphicRef54417 \">table 1</a>). The defective enzymes involved in GSD I are mainly active in the liver and kidney. Patients present with manifestations related to hypoglycemia around three to four months of age. The diagnosis is confirmed by genetic testing. Treatment is focused on maintenance of physiologic glucose levels.</p><p>GSD I is reviewed in detail here. Other GSDs are reviewed separately. (See <a href=\"topic.htm?path=liver-glycogen-synthase-deficiency-glycogen-storage-disease-0\" class=\"medical medical_review\">&quot;Liver glycogen synthase deficiency (glycogen storage disease 0)&quot;</a> and <a href=\"topic.htm?path=lysosomal-acid-alpha-glucosidase-deficiency-pompe-disease-glycogen-storage-disease-ii-acid-maltase-deficiency\" class=\"medical medical_review\">&quot;Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)&quot;</a> and <a href=\"topic.htm?path=lysosome-associated-membrane-protein-2-deficiency-glycogen-storage-disease-iib-danon-disease\" class=\"medical medical_review\">&quot;Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)&quot;</a> and <a href=\"topic.htm?path=glycogen-debrancher-deficiency-glycogen-storage-disease-iii\" class=\"medical medical_review\">&quot;Glycogen debrancher deficiency (glycogen storage disease III)&quot;</a> and <a href=\"topic.htm?path=glycogen-branching-enzyme-deficiency-glycogen-storage-disease-iv-andersen-disease\" class=\"medical medical_review\">&quot;Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)&quot;</a> and <a href=\"topic.htm?path=myophosphorylase-deficiency-glycogen-storage-disease-v-mcardle-disease\" class=\"medical medical_review\">&quot;Myophosphorylase deficiency (glycogen storage disease V, McArdle disease)&quot;</a> and <a href=\"topic.htm?path=liver-phosphorylase-deficiency-glycogen-storage-disease-vi-hers-disease\" class=\"medical medical_review\">&quot;Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)&quot;</a> and <a href=\"topic.htm?path=phosphofructokinase-deficiency-glycogen-storage-disease-vii-tarui-disease\" class=\"medical medical_review\">&quot;Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)&quot;</a>.)</p><p>A broader overview of GSD is also presented separately. (See <a href=\"topic.htm?path=overview-of-inherited-disorders-of-glucose-and-glycogen-metabolism\" class=\"medical medical_review\">&quot;Overview of inherited disorders of glucose and glycogen metabolism&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence of GSD I is <span class=\"nowrap\">1/100,000</span> live births [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/1\" class=\"abstract_t\">1</a>]. It is one of the most common types of GSDs.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS AND CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The hydrolysis and transport of glucose-6-phosphate (G6P) require a catalytic hydrolase and microsomal transporters for glucose-6-phosphate (G6P), pyrophosphate, and glucose (<a href=\"image.htm?imageKey=PEDS%2F81164\" class=\"graphic graphic_figure graphicRef81164 \">figure 1</a>). GSD I is caused by defects in the hydrolase (phosphatase) or translocase:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>GSD Ia</strong> is due to a deficiency in the G6P hydrolase activity and comprises over 80 percent of cases of GSD I. The enzyme glucose-6-phosphatase is mainly expressed in the liver and kidney.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>GSD Ib</strong> (G6P transporter deficiency) is caused by a defect in the G6P translocase that is functionally associated with glucose-6-phosphatase [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/2\" class=\"abstract_t\">2</a>]. The translocase is ubiquitously expressed and functions as both a G6P transporter and a phosphate antiporter [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/3\" class=\"abstract_t\">3</a>]. The enzyme may also play a role in neutrophil differentiation and immune modulation [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p/><p>Expression of glucose-6-phosphatase appears to be modulated by steroid receptor coactivator 2 (SRC-2) [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/6\" class=\"abstract_t\">6</a>]. Ablation of SRC-2 in a mouse model resulted in a phenotype similar to that of G6PD, although this defect has not been reported in humans.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">GENETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GSD I is an autosomal recessive disorder. The genes responsible for GSD I have been isolated and mutations described in both type Ia and Ib patients. The glucose-6-phosphatase gene, <em>G6PC</em>, encodes the hydrolase and is located on chromosome 17q21. The gene encoding glucose-6-phosphate translocase, solute carrier family 37 member 4 (<em>SLC37A4</em>)<em>,</em> is localized to chromosome 11q23.</p><p>Over 100 mutations have been identified in the <em>G6PC</em> gene [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Most are <span class=\"nowrap\">missense/nonsense</span> mutations. Small deletions, insertions, and spice-site mutations have also been reported. Several common mutations exist in patients with GSD Ia:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>c.247C&gt;T (R83C) and c.1039C&gt;T (Q347X) are the most prevalent mutations found in Caucasians [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>c.379_380dupTA (p.Tyr128Thrfs) and c.247C&gt;T (R83C) are most prevalent in Hispanics [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>c.648G&gt;T (L216L), a splicing mutation, and c.248G&gt;A (R83H) are the most prevalent mutations in the Chinese population [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/7,9,10\" class=\"abstract_t\">7,9,10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>c.648G&gt;T accounts for 91 percent of mutant alleles in Japan [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/7,11\" class=\"abstract_t\">7,11</a>] and 75 percent of mutant alleles in Korea [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>c.247C&gt;T (R83C) accounts for 98 percent of mutations in the Ashkenazi Jewish population [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p>Over 100 mutations in <em>SLC37A4</em> have been identified in patients with GSD Ib [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/8\" class=\"abstract_t\">8</a>]. The majority are missense and nonsense mutations, but a significant number of deletions and splicing mutations are also seen.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>c.1015G&gt;T (G339C) and c.1042_1043delCT are the most common mutations in Caucasians [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/10,13\" class=\"abstract_t\">10,13</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>c.352T&gt;C (W118R) accounts for 50 percent of mutant alleles in the Japanese population [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/10,14\" class=\"abstract_t\">10,14</a>].</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Affected patients most commonly present between three to six months of age with hepatomegaly, signs and symptoms of hypoglycemia (such as seizures), poor growth, and doll-like facies. In a report from the collaborative European study on GSD I, patients with GSD Ia and GSD Ib presented at a median age of six months (range 1 day to 12 years) and four months (range 1 day to 4 years), respectively [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/15\" class=\"abstract_t\">15</a>]. The majority of both types presented before one year of age in this series.</p><p>In the European study, the following were the dominant presenting features [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/15\" class=\"abstract_t\">15</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Protruding abdomen &ndash; 83 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Metabolic derangement, including hypoglycemia, lactic acidosis, hypertriglyceridemia, and hyperuricemia &ndash; 71 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Growth failure (short stature, thin legs) &ndash; 25 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrent bacterial infections &ndash; 3 percent in GSD Ia, 41 percent in GSD Ib</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Muscular hypotonia &ndash; 13 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Delayed psychomotor development &ndash; 7 percent</p><p/><p class=\"headingAnchor\" id=\"H1052937\"><span class=\"h2\">Metabolic hypoglycemia/lactic acidosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypoglycemia is the hallmark finding in patients with GSD I. Affected individuals have poor fasting tolerance, especially infants and young children, and may develop hypoglycemia and lactic acidosis within a few hours after a meal. Patients appear to adapt to hypoglycemia and may be asymptomatic despite low blood glucose values (&lt;40 <span class=\"nowrap\">mg/dL)</span>.</p><p class=\"headingAnchor\" id=\"H600479553\"><span class=\"h2\">Hyperuricemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many patients have hyperuricemia, which is secondary to decreased renal clearance and increased production via degradation of adenine nucleotides [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/16\" class=\"abstract_t\">16</a>]. Gout rarely develops before puberty [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H600479587\"><span class=\"h2\">Hyperlipidemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Marked hyperlipidemia, especially hypertriglyceridemia, occurs and can lead to xanthoma formation and pancreatitis. De novo triglyceride synthesis has been shown to increase over 10-fold in affected individuals, and the conversion of very-low-density lipoprotein (VLDL) to low-density lipoprotein (LDL) is retarded [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/17\" class=\"abstract_t\">17</a>]. The relationship between hyperlipidemia and cardiovascular disease in patients with GSD I is unclear [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/18\" class=\"abstract_t\">18</a>]. The finding of increased carotid intima media thickening suggests that the risk of vascular dysfunction may be increased, but case series have yielded inconsistent observations regarding vascular dysfunction and markers of cardiovascular risk [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/18-21\" class=\"abstract_t\">18-21</a>].</p><p class=\"headingAnchor\" id=\"H600479663\"><span class=\"h2\">Hematologic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anemia, while uncommon in treated patients, can be observed in both the pediatric and adult populations. It can result from chronic kidney disease, nutritional deficiencies, hemorrhage of hepatic adenomas, enterocolitis in type Ib patients, and other factors [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>]. Platelet dysfunction, which is related to dyslipidemia, can result in easy bruising and epistaxis. Patients with GSD Ib also have intermittent or chronic neutropenia and neutrophil dysfunction [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/1\" class=\"abstract_t\">1</a>]. In a report from a European registry of 57 GSD Ib patients, neutropenia occurred in 54 [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/23\" class=\"abstract_t\">23</a>]. It was documented before one year of age in 64 percent of patients but was first noted between six and nine years in 18 percent. Neutropenia was intermittent without a clear cyclical course in 45 patients and persistent in 5. (See <a href=\"topic.htm?path=congenital-neutropenia\" class=\"medical medical_review\">&quot;Congenital neutropenia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Gastrointestinal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Perioral and perianal infections, abscesses, and Crohn-like inflammatory bowel disease (IBD) are common in GSD Ib [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/24\" class=\"abstract_t\">24</a>]. (See <a href=\"topic.htm?path=epidemiology-and-environmental-factors-in-inflammatory-bowel-disease-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Endocrine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Short stature is common if patients are not appropriately managed [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/10\" class=\"abstract_t\">10</a>]. Puberty is often delayed, and menstrual cycles are frequently irregular [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/25\" class=\"abstract_t\">25</a>]. Polycystic ovaries and menorrhagia are observed. Fertility is not thought to be reduced, and successful pregnancies without the use of assistive reproductive measures have been reported [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22,25,26\" class=\"abstract_t\">22,25,26</a>]. An increased prevalence of thyroid autoimmunity and hypothyroidism has been reported in patients with GSD Ib [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/27\" class=\"abstract_t\">27</a>]. Vitamin D levels are often low [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Renal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Renal disease results from glycogen accumulation in the kidney. Proteinuria, hematuria, nephrocalcinosis, and altered creatinine clearance typically follow a period of asymptomatic hyperfiltration. Stones result both from hypercalciuria and hyperuricosuria. The kidney appears enlarged, and histologic examination reveals focal segmental glomerulosclerosis and interstitial fibrosis [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/16,29-31\" class=\"abstract_t\">16,29-31</a>]. (See <a href=\"topic.htm?path=epidemiology-classification-and-pathogenesis-of-focal-segmental-glomerulosclerosis\" class=\"medical medical_review\">&quot;Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis&quot;</a>.)</p><p>Hypertension (<a href=\"topic.htm?path=calculator-blood-pressure-percentiles-for-boys-0-to-17-years-old-revised-2017\" class=\"calc calc_professional\">calculator 1</a> and <a href=\"topic.htm?path=calculator-blood-pressure-percentiles-for-girls-0-to-17-years-old-revised-2017\" class=\"calc calc_professional\">calculator 2</a>) is common, and onset is typically in the second decade or later. A subset of patients develop progressive renal insufficiency and end-stage renal disease [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/29\" class=\"abstract_t\">29</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Neurologic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with GSD I are at risk for hypoglycemic seizures. Intelligence quotient (IQ) is normal, but brain function and structure may be altered as a result of recurrent, severe hypoglycemia. In one study comparing brain function and morphology in patients with GSD I and age- and sex-matched controls, subjects with GSD I had increased prevalence of abnormal electroencephalograms (26 versus 3 percent), visual evoked potentials (38 versus 8 percent), somatosensory evoked potentials (23 versus 0 percent), brainstem auditory evoked potentials (16 versus 0 percent), and abnormal magnetic resonance imaging (MRI) studies (57 versus 0 percent) [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/32\" class=\"abstract_t\">32</a>]. MRI abnormalities included dilation of the occipital horns <span class=\"nowrap\">and/or</span> hyperintensity of subcortical white matter in the occipital or parietal lobes. Some of these abnormalities correlated with the frequency of hypoglycemic episodes requiring hospitalization, but the contribution of other factors, directly or indirectly related to GSD I, remains unclear.</p><p class=\"headingAnchor\" id=\"H1052957\"><span class=\"h2\">Hepatic adenomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most adults develop liver adenomas in the second to third decade of life. The adenomas may lead to intrahepatic hemorrhage and undergo malignant transformation in approximately 10 percent of cases [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/33\" class=\"abstract_t\">33</a>]. Enlargement of pre-existing hepatic adenomas or appearance of new adenomas during pregnancy has been reported in GSD I patients [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H646313187\"><span class=\"h2\">Bone density</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Osteoporosis is seen in over one-half of adult patients with GSD Ia and Ib [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/34\" class=\"abstract_t\">34</a>]. Decreased bone mineral density is in part due to dietary restriction of lactose and galactose that leads to vitamin D deficiency.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GSD I should be suspected in patients with hypoglycemia, lactic acidemia, hypertriglyceridemia, hyperuricemia, and hepatomegaly, with or without neutropenia.</p><p>DNA testing is necessary to confirm the diagnosis of GSD Ia or Ib. Commercial sequencing of <em>G6PC</em> (glucose-6-phosphatase gene) and <em>SLC37A4 </em>(glucose-6-phosphate translocase gene) is widely available. Liver biopsies for histologic studies and enzyme analysis were performed historically but are rarely necessary nowadays. Liver histology, if performed, demonstrates prominent storage of glycogen and considerable steatosis with minimal fibrosis.</p><p>A guideline for the diagnosis and management of GSD I is available from the American College of Medical Genetics and Genomics [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>]. Our approach is consistent with the guideline.</p><p class=\"headingAnchor\" id=\"H455049781\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main diagnoses to consider are the other hepatic forms of GSD that cause hypoglycemia. These are types 0, III, VI, and IX (<a href=\"image.htm?imageKey=PEDS%2F54417\" class=\"graphic graphic_table graphicRef54417 \">table 1</a>). Patients with GSD type III tend to have milder hypoglycemia and present later in life. In addition, uric acid and lactic acid are typically normal. Ketosis is much more pronounced in GSD types 0, III, VI, and IX compared with type I. GSD type 0 does not cause hepatomegaly. Ultimately, genetic testing is necessary to confirm the specific type of GSD.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with GSD I should be managed by an experienced metabolic team including a biochemical geneticist, dietitian, nurse, and social worker. Other specialists may include a nephrologist, hepatologist, hematologist, and endocrinologist. A guideline for the diagnosis and management of GSD I is available from the American College of Medical Genetics and Genomics [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>]. Our management approach is consistent with the guideline.</p><p>The goal of treatment is the maintenance of physiologic glucose levels. Other clinical and biochemical parameters, such as lactic acidemia and hypertriglyceridemia, improve in parallel with improved glucose control [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/35\" class=\"abstract_t\">35</a>].</p><p>Guidelines for the management of GSD I were published by the collaborative European study on GSD I [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/36\" class=\"abstract_t\">36</a>]. The following recommendations were made for appropriate biochemical targets:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preprandial blood glucose &gt;3.5 to 4.0 <span class=\"nowrap\">mmol/L</span> (63 to 72 <span class=\"nowrap\">mg/dL)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urine <span class=\"nowrap\">lactate/creatinine</span> ratio &lt;0.06 <span class=\"nowrap\">mmol/mmol</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum uric acid concentration in high normal range for age</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Venous blood base excess &gt;-5 <span class=\"nowrap\">mmol/L</span> and venous blood bicarbonate &gt;20 <span class=\"nowrap\">mmol/L</span> (20 <span class=\"nowrap\">mEq/L)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum triglyceride concentration &lt;6.0 <span class=\"nowrap\">mmol/L</span> (531 <span class=\"nowrap\">mg/dL)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal fecal alpha-1 antitrypsin concentration for GSD Ib</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Body mass index between 0.0 and + 2.0 standard deviations (<a href=\"topic.htm?path=calculator-body-mass-index-bmi-percentiles-for-boys-2-to-20-years\" class=\"calc calc_professional\">calculator 3</a> and <a href=\"topic.htm?path=calculator-body-mass-index-bmi-percentiles-for-girls-2-to-20-years\" class=\"calc calc_professional\">calculator 4</a>)</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Prevention of hypoglycemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Glucose concentrations are maintained with frequent oral administration of glucose, usually in the form of uncooked cornstarch, which is a glucose polymer. Long-term treatment with uncooked cornstarch improves growth in GSD I patients [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/37-39\" class=\"abstract_t\">37-39</a>]. Adverse effects of uncooked cornstarch include diarrhea, increased flatulence, and excess weight gain. Other commercial glucose polymer products are available and may allow longer fasting intervals between meals [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/40\" class=\"abstract_t\">40</a>].</p><p>The dose of uncooked cornstarch is 1.6 <span class=\"nowrap\">g/kg</span> every three to four hours for young children and 1.7 to 2.5 <span class=\"nowrap\">g/kg</span> every four to six hours for older children, adolescents, and adults (1 tablespoon equals approximately 8.6 grams) [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>]. Since infants may not digest cornstarch well, they can be breastfed or given formula that is lactose free with <a href=\"topic.htm?path=maltodextrin-drug-information\" class=\"drug drug_general\">maltodextrin</a> added [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/36\" class=\"abstract_t\">36</a>]. After six months, the maltodextrin can be replaced by uncooked rice starch or cornstarch.</p><p>Infants may require continuous feeds overnight through a nasogastric or gastrostomy tube. An optimal infusion should provide 8 to 10 <span class=\"nowrap\">mg/kg/minute</span> of glucose for an infant and 4 to 8 <span class=\"nowrap\">mg/kg/minute</span> of glucose in an older child [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>]. After one year of age, children should be given at least three daily meals with uncooked cornstarch and frequent snacks in between. In many cases, a dose of cornstarch is needed during the night.</p><p><a href=\"topic.htm?path=diazoxide-drug-information\" class=\"drug drug_general\">Diazoxide</a> has been shown to improve glucose control, probably by inhibiting glucose-induced insulin release, although this agent is not routinely used [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H1052964\"><span class=\"h2\">Nutrition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Working with a metabolic dietitian is essential in caring for patients with GSD I. Complex carbohydrates should comprise the majority of the diet (60 to 70 percent of the total energy intake). Sugar, fruits, fruit juices, high-fructose corn syrup, and <a href=\"topic.htm?path=sorbitol-drug-information\" class=\"drug drug_general\">sorbitol</a> should be avoided. Lactose, galactose, fructose, and sucrose should be limited since they also depend upon glucose-6-phosphatase activity for metabolism. In infants, a soy-based formula must be used. A high-protein diet is not useful to maintain glucose in GSD I, since gluconeogenesis also depends upon hydrolysis of glucose-6-phosphate (G6P). Essential vitamins and minerals, especially calcium, should be provided through the diet or by supplementation, if needed.</p><p class=\"headingAnchor\" id=\"H600480232\"><span class=\"h2\">Treatment of lactic acidosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lactic acidosis, if persistent, can be treated with oral citrate or bicarbonate administration, which also alkalinizes the urine and decreases the risk of urolithiasis and nephrocalcinosis. Alkalinization with <a href=\"topic.htm?path=potassium-citrate-tablet-drug-information\" class=\"drug drug_general\">potassium citrate</a> (5 to 10 mEq every 12 hours orally) is preferred over bicarbonate because hypocitraturia appears to worsen with age in GSD Ia [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/42\" class=\"abstract_t\">42</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Treatment of hyperuricemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no consensus as to when to treat hyperuricemia with medications. <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">Allopurinol</a> lowers uric acid levels and can be used in patients with persistently elevated uric acid or with recurrent attacks of gout. <a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">Colchicine</a> may be used during acute attacks. Use of medium-chain triglyceride oil was shown in a small study to improve uric acid levels and reduce carbohydrate requirements [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H600480175\"><span class=\"h2\">Treatment of hyperlipidemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lipid-lowering agents such as 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors and fibrate may be used. Dietary interventions (eg, administration of medium-chain triglyceride milk) may be effective at reducing triglyceride and lactic acid levels by improving fatty acid oxidation and reducing glycolysis but require additional evaluation [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/44\" class=\"abstract_t\">44</a>]. However, hyperlipidemia in patients with GSD I typically only responds partially to drug therapy <span class=\"nowrap\">and/or</span> dietary measures. Resolution after liver transplantation has been reported [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=dyslipidemia-in-children-management\" class=\"medical medical_review\">&quot;Dyslipidemia in children: Management&quot;</a> and <a href=\"topic.htm?path=hypertriglyceridemia\" class=\"medical medical_review\">&quot;Hypertriglyceridemia&quot;</a>.)</p><p>Fish oil does not persistently lower serum triglyceride and cholesterol concentration and may increase atherogenesis by increasing lipoprotein oxidation [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"headingAnchor\" id=\"H600480298\"><span class=\"h2\">Neutropenia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with GSD Ib and neutropenia should be treated with granulocyte colony-stimulating factor (G-CSF) [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/46-48\" class=\"abstract_t\">46-48</a>]. In a report from the European registry, G-CSF increased the neutrophil count, decreased the frequency and severity of infections, and subjectively improved the severity of inflammatory bowel disease (IBD) [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/48\" class=\"abstract_t\">48</a>]. Splenomegaly was the most serious complication of G-CSF and occurred in 4 of 18 patients treated.</p><p>Reactive oxygen species are thought to play a role in activating apoptosis in neutrophils of patients with GSD Ib, suggesting that antioxidant therapy may be beneficial. Supplementation with <a href=\"topic.htm?path=vitamin-e-drug-information\" class=\"drug drug_general\">vitamin E</a> has been shown to increase mean neutrophil count, decrease the frequency and severity of infections, and, in some cases, allow for dose reduction of G-CSF [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/49,50\" class=\"abstract_t\">49,50</a>].These findings show promise as an adjunct or alternative treatment but should be replicated in larger, placebo-controlled trials before vitamin E therapy can be routinely suggested for the treatment of patients with GSD Ib.</p><p class=\"headingAnchor\" id=\"H646313208\"><span class=\"h2\">Anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of anemia may include iron supplementation and erythropoietin, depending upon the severity [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Inflammatory bowel disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Crohn-like IBD is treated with the usual approach that includes 5-aminosalicylic acid agents and antibiotics. Patients have also responded to G-CSF, which is used to treat neutropenia. Successful treatment of refractory GSD-related IBD with <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> has been reported [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/51\" class=\"abstract_t\">51</a>]. (See <a href=\"topic.htm?path=overview-of-the-medical-management-of-mild-low-risk-crohn-disease-in-adults\" class=\"medical medical_review\">&quot;Overview of the medical management of mild (low risk) Crohn disease in adults&quot;</a> and <a href=\"topic.htm?path=overview-of-medical-management-of-high-risk-adult-patients-with-moderate-to-severe-crohn-disease\" class=\"medical medical_review\">&quot;Overview of medical management of high-risk, adult patients with moderate to severe Crohn disease&quot;</a> and <a href=\"topic.htm?path=overview-of-the-management-of-crohn-disease-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Overview of the management of Crohn disease in children and adolescents&quot;</a> and <a href=\"#H600480298\" class=\"local\">'Neutropenia'</a> above.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Short stature</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Growth hormone does not affect the final height and should not be used, because it can lead to the development of or an increase in the size or number of liver adenomas [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22,36\" class=\"abstract_t\">22,36</a>]. Good metabolic control leads to improved growth parameters (height and weight).</p><p class=\"headingAnchor\" id=\"H646313228\"><span class=\"h2\">Osteoporosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dual-energy x-ray absorptiometry (DXA) scans and vitamin D 25-OH levels should be checked regularly to monitor bone density and need for vitamin D supplementation [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H1892107488\"><span class=\"h2\">Renal disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A renal ultrasound should be obtained annually to assess for renal enlargement and nephrolithiasis. Blood urea nitrogen, creatinine, urinalysis, quantitation of microalbumin, and other renal function studies should be checked at routine intervals, typically annually in children and every six months in adults [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>]. An angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) should be started in patients with persistent microalbuminuria to decrease deterioration of renal function [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22,36,52\" class=\"abstract_t\">22,36,52</a>]. Hypertension that persists despite ACE inhibition should also be treated. Kidney transplant can be performed in patients with end-stage renal disease.</p><p class=\"headingAnchor\" id=\"H455049813\"><span class=\"h2\">Hepatocellular carcinoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatocellular carcinoma (HCC) is a known late complication GSD I [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/53,54\" class=\"abstract_t\">53,54</a>]. Adenoma to HCC transformation may occur despite good metabolic control. A liver ultrasound should be performed every 12 to 24 months in children &lt;18 years of age to screen for HCC. Computed tomography (CT) or magnetic resonance imaging (MRI) with contrast is recommended every 6 to 12 months in older patients [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"abstract_t\">22</a>]. Oral contraceptive pills are contraindicated in women with GSD I since estrogen increases the risk for hepatic adenomas. However, progestin-only contraceptives are an option [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22,25\" class=\"abstract_t\">22,25</a>]. During pregnancy, adenomas must be monitored due to the risk for enlargement and rupture. (See <a href=\"#H1052957\" class=\"local\">'Hepatic adenomas'</a> above.)</p><p class=\"headingAnchor\" id=\"H1226450745\"><span class=\"h2\">Pulmonary hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An echocardiogram should be performed starting at 10 years of age to screen for pulmonary hypertension [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22,35\" class=\"abstract_t\">22,35</a>]. This study should be repeated every three years or sooner if clinically indicated.</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">Liver transplantation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Liver transplantation is indicated in GSD I patients with poor metabolic control, worsening adenomas, HCC, <span class=\"nowrap\">and/or</span> liver failure. The 1-, 5-, and 10-year survival rates are 82, 76, and 64 percent, respectively [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/55\" class=\"abstract_t\">55</a>]. The procedure greatly improves metabolic control, resulting in resolution of hypoglycemic episodes and lactic acidosis and improvement of hypertriglyceridemia and hyperuricemia [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/56\" class=\"abstract_t\">56</a>]. Patients can return to a normal diet after liver transplantation. Growth deficiency and neutropenia often persist in GSD Ib after transplantation.</p><p>Some patients with GSD Ia develop renal failure after liver transplant, although it is unclear if this is due to natural disease progression or an adverse effect of immunosuppressive medications. Combined liver and kidney transplant can be done [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/57-60\" class=\"abstract_t\">57-60</a>].</p><p>Hepatocyte transplantation may be a future alternative to liver transplantation, but further studies are needed [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/61\" class=\"abstract_t\">61</a>].</p><p class=\"headingAnchor\" id=\"H1108005130\"><span class=\"h2\">Other (or future) therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical trials for gene therapy for GSD Ia are underway.</p><p class=\"headingAnchor\" id=\"H161035966\"><span class=\"h1\">OUTCOME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Complications due to GSD I persist in adults. In one report, long-term outcomes were evaluated in 37 patients with GSD Ia and five patients with GSD Ib who were &ge;18 years of age [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/62\" class=\"abstract_t\">62</a>]. The following outcomes were noted:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatomegaly &ndash; 100 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Short stature &ndash; 90 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperuricemia &ndash; 89 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anemia &ndash; 81 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypercholesterolemia &ndash; 76 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased serum triglycerides &ndash; 100 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatic adenomas &ndash; 75 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Proteinuria or microalbuminuria &ndash; 67 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Renal calcifications &ndash; 65 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteopenia or fractures &ndash; 27 percent</p><p/><p>Some patients develop pulmonary hypertension [<a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/63,64\" class=\"abstract_t\">63,64</a>].</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Glucose-6-phosphatase deficiency (G6PD; glycogen storage disease type I [GSD I]), also known as von Gierke disease, is an autosomal recessive disorder caused by a deficiency of glucose-6-phosphate (G6P) hydrolase (type Ia) or G6P translocase (type Ib) (<a href=\"image.htm?imageKey=PEDS%2F81164\" class=\"graphic graphic_figure graphicRef81164 \">figure 1</a>). (See <a href=\"#H3\" class=\"local\">'Pathogenesis and classification'</a> above and <a href=\"#H4\" class=\"local\">'Genetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Affected patients typically present in early infancy with growth failure, hepatomegaly, hypoglycemia, seizures, <span class=\"nowrap\">and/or</span> lactic acidosis. Additional manifestations include renal disease, hyperuricemia, hypertriglyceridemia, and, in patients with type Ib GSD, recurrent infections due to neutropenia. (See <a href=\"#H5\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of GSD I is confirmed by gene sequencing. (See <a href=\"#H14\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H4\" class=\"local\">'Genetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The goal of treatment is to maintain physiologic glucose levels. Other biochemical parameters, such as lactic acidemia and hypertriglyceridemia, improve in parallel with improved glucose control. (See <a href=\"#H15\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Glucose concentrations are maintained with regular meals, snacks, and administration of uncooked cornstarch. (See <a href=\"#H18\" class=\"local\">'Prevention of hypoglycemia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Additional treatment measures may be necessary for hyperuricemia, hyperlipidemia, microalbuminuria, hypertension, neutropenia, and inflammatory bowel disease (IBD). (See <a href=\"#H15\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1052820\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge William J Craigen, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/1\" class=\"nounderline abstract_t\">Melis D, Fulceri R, Parenti G, et al. Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature. Eur J Pediatr 2005; 164:501.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/2\" class=\"nounderline abstract_t\">Gerin I, Veiga-da-Cunha M, Achouri Y, et al. Sequence of a putative glucose 6-phosphate translocase, mutated in glycogen storage disease type Ib. FEBS Lett 1997; 419:235.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/3\" class=\"nounderline abstract_t\">Chen SY, Pan CJ, Nandigama K, et al. The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic. FASEB J 2008; 22:2206.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/4\" class=\"nounderline abstract_t\">Ihara K, Nomura A, Hikino S, et al. Quantitative analysis of glucose-6-phosphate translocase gene expression in various human tissues and haematopoietic progenitor cells. J Inherit Metab Dis 2000; 23:583.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/5\" class=\"nounderline abstract_t\">Chen LY, Shieh JJ, Lin B, et al. Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. Hum Mol Genet 2003; 12:2547.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/6\" class=\"nounderline abstract_t\">Chopra AR, Louet JF, Saha P, et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 2008; 322:1395.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/7\" class=\"nounderline abstract_t\">Chou JY, Mansfield BC. Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum Mutat 2008; 29:921.</a></li><li class=\"breakAll\">The Human Gene Mutation Database at http://www.hgmd.cf.ac.uk/ac/index.php (Accessed on September 23, 2016).</li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/9\" class=\"nounderline abstract_t\">Lei KJ, Chen YT, Chen H, et al. Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus. Am J Hum Genet 1995; 57:766.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/10\" class=\"nounderline abstract_t\">Matern D, Seydewitz HH, Bali D, et al. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 2002; 161 Suppl 1:S10.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/11\" class=\"nounderline abstract_t\">Akanuma J, Nishigaki T, Fujii K, et al. Glycogen storage disease type Ia: molecular diagnosis of 51 Japanese patients and characterization of splicing mutations by analysis of ectopically transcribed mRNA from lymphoblastoid cells. Am J Med Genet 2000; 91:107.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/12\" class=\"nounderline abstract_t\">Ekstein J, Rubin BY, Anderson SL, et al. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet A 2004; 129A:162.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/13\" class=\"nounderline abstract_t\">Veiga-da-Cunha M, Gerin I, Chen YT, et al. The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a. Eur J Hum Genet 1999; 7:717.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/14\" class=\"nounderline abstract_t\">Kure S, Suzuki Y, Matsubara Y, et al. Molecular analysis of glycogen storage disease type Ib: identification of a prevalent mutation among Japanese patients and assignment of a putative glucose-6-phosphate translocase gene to chromosome 11. Biochem Biophys Res Commun 1998; 248:426.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/15\" class=\"nounderline abstract_t\">Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161 Suppl 1:S20.</a></li><li class=\"breakAll\">Chen YT, Kishnani PS, Koeberl D. Glycogen Storage Diseases. The Online Metabolic and Molecular Bases of Inherited Disease. http://ommbid.mhmedical.com/ommbid-index.aspx (Accessed on October 22, 2014).</li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/17\" class=\"nounderline abstract_t\">Bandsma RH, Prinsen BH, van Der Velden Mde S, et al. Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res 2008; 63:702.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/18\" class=\"nounderline abstract_t\">Bernier AV, Correia CE, Haller MJ, et al. Vascular dysfunction in glycogen storage disease type I. J Pediatr 2009; 154:588.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/19\" class=\"nounderline abstract_t\">Ubels FL, Rake JP, Slaets JP, et al. Is glycogen storage disease 1a associated with atherosclerosis? Eur J Pediatr 2002; 161 Suppl 1:S62.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/20\" class=\"nounderline abstract_t\">Lee PJ, Celermajer DS, Robinson J, et al. Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. Atherosclerosis 1994; 110:95.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/21\" class=\"nounderline abstract_t\">Carvalho PM, Silva NJ, Dias PG, et al. Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases. J Diabetes Metab Disord 2013; 12:25.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/22\" class=\"nounderline abstract_t\">Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med 2014; 16:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/23\" class=\"nounderline abstract_t\">Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 2000; 137:187.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/24\" class=\"nounderline abstract_t\">Roe TF, Thomas DW, Gilsanz V, et al. Inflammatory bowel disease in glycogen storage disease type Ib. J Pediatr 1986; 109:55.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/25\" class=\"nounderline abstract_t\">Sechi A, Deroma L, Lapolla A, et al. Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study. J Inherit Metab Dis 2013; 36:83.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/26\" class=\"nounderline abstract_t\">Ryan IP, Havel RJ, Laros RK Jr. Three consecutive pregnancies in a patient with glycogen storage disease type IA (von Gierke's disease). Am J Obstet Gynecol 1994; 170:1687.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/27\" class=\"nounderline abstract_t\">Melis D, Pivonello R, Parenti G, et al. Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I. J Pediatr 2007; 150:300.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/28\" class=\"nounderline abstract_t\">Banugaria SG, Austin SL, Boney A, et al. Hypovitaminosis D in glycogen storage disease type I. Mol Genet Metab 2010; 99:434.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/29\" class=\"nounderline abstract_t\">Chen YT, Coleman RA, Scheinman JI, et al. Renal disease in type I glycogen storage disease. N Engl J Med 1988; 318:7.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/30\" class=\"nounderline abstract_t\">Chen YT. Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment. Pediatr Nephrol 1991; 5:71.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/31\" class=\"nounderline abstract_t\">Reitsma-Bierens WC. Renal complications in glycogen storage disease type I. Eur J Pediatr 1993; 152 Suppl 1:S60.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/32\" class=\"nounderline abstract_t\">Melis D, Parenti G, Della Casa R, et al. Brain damage in glycogen storage disease type I. J Pediatr 2004; 144:637.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/33\" class=\"nounderline abstract_t\">Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993; 152 Suppl 1:S63.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/34\" class=\"nounderline abstract_t\">Minarich LA, Kirpich A, Fiske LM, Weinstein DA. Bone mineral density in glycogen storage disease type Ia and Ib. Genet Med 2012.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/35\" class=\"nounderline abstract_t\">Fernandes J, Smit GP, Berger R. Outcome of the treatment of glycogen storage disease. Acta Paediatr Jpn 1988; 30:457.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/36\" class=\"nounderline abstract_t\">Rake JP, Visser G, Labrune P, et al. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161 Suppl 1:S112.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/37\" class=\"nounderline abstract_t\">Chen YT, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 1984; 310:171.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/38\" class=\"nounderline abstract_t\">Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr 2002; 161 Suppl 1:S35.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/39\" class=\"nounderline abstract_t\">Chen YT, Bazzarre CH, Lee MM, et al. Type I glycogen storage disease: nine years of management with cornstarch. Eur J Pediatr 1993; 152 Suppl 1:S56.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/40\" class=\"nounderline abstract_t\">Correia CE, Bhattacharya K, Lee PJ, et al. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr 2008; 88:1272.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/41\" class=\"nounderline abstract_t\">Nuoffer JM, Mullis PE, Wiesmann UN. Treatment with low-dose diazoxide in two growth-retarded prepubertal girls with glycogen storage disease type Ia resulted in catch-up growth. J Inherit Metab Dis 1997; 20:790.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/42\" class=\"nounderline abstract_t\">Weinstein DA, Somers MJ, Wolfsdorf JI. Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 2001; 138:378.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/43\" class=\"nounderline abstract_t\">Das AM, L&uuml;cke T, Meyer U, et al. Glycogen storage disease type 1: impact of medium-chain triglycerides on metabolic control and growth. Ann Nutr Metab 2010; 56:225.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/44\" class=\"nounderline abstract_t\">Nagasaka H, Hirano K, Ohtake A, et al. Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk. Eur J Pediatr 2007; 166:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/45\" class=\"nounderline abstract_t\">Bandsma RH, Rake JP, Visser G, et al. Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a. J Pediatr 2002; 140:256.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/46\" class=\"nounderline abstract_t\">Schroten H, Roesler J, Breidenbach T, et al. Granulocyte and granulocyte-macrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type Ib. J Pediatr 1991; 119:748.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/47\" class=\"nounderline abstract_t\">Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 2002; 161 Suppl 1:S46.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/48\" class=\"nounderline abstract_t\">Visser G, Rake JP, Labrune P, et al. Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002; 161 Suppl 1:S120.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/49\" class=\"nounderline abstract_t\">Melis D, Della Casa R, Parini R, et al. Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b. Eur J Pediatr 2009; 168:1069.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/50\" class=\"nounderline abstract_t\">Melis D, Minopoli G, Balivo F, et al. Vitamin E Improves Clinical Outcome of Patients Affected by Glycogen Storage Disease Type Ib. JIMD Rep 2016; 25:39.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/51\" class=\"nounderline abstract_t\">Davis MK, Rufo PA, Polyak SF, Weinstein DA. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J Inherit Metab Dis 2008; 31 Suppl 3:505.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/52\" class=\"nounderline abstract_t\">Melis D, Parenti G, Gatti R, et al. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study. Clin Endocrinol (Oxf) 2005; 63:19.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/53\" class=\"nounderline abstract_t\">Franco LM, Krishnamurthy V, Bali D, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 2005; 28:153.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/54\" class=\"nounderline abstract_t\">Limmer J, Fleig WE, Leupold D, et al. Hepatocellular carcinoma in type I glycogen storage disease. Hepatology 1988; 8:531.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/55\" class=\"nounderline abstract_t\">Maheshwari A, Rankin R, Segev DL, Thuluvath PJ. Outcomes of liver transplantation for glycogen storage disease: a matched-control study and a review of literature. Clin Transplant 2012; 26:432.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/56\" class=\"nounderline abstract_t\">Iyer SG, Chen CL, Wang CC, et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transpl 2007; 13:848.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/57\" class=\"nounderline abstract_t\">Demirci G, Becker T, Nyibata M, et al. Results of combined and sequential liver-kidney transplantation. Liver Transpl 2003; 9:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/58\" class=\"nounderline abstract_t\">Belingheri M, Ghio L, Sala A, et al. Combined liver-kidney transplantation in glycogen storage disease Ia: a case beyond the guidelines. Liver Transpl 2007; 13:762.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/59\" class=\"nounderline abstract_t\">Panaro F, Andorno E, Basile G, et al. Simultaneous liver-kidney transplantation for glycogen storage disease type IA (von Gierke's disease). Transplant Proc 2004; 36:1483.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/60\" class=\"nounderline abstract_t\">Marega A, Fregonese C, Tulissi P, et al. Preemptive liver-kidney transplantation in von Gierke disease: a case report. Transplant Proc 2011; 43:1196.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/61\" class=\"nounderline abstract_t\">Muraca M, Gerunda G, Neri D, et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002; 359:317.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/62\" class=\"nounderline abstract_t\">Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994; 120:218.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/63\" class=\"nounderline abstract_t\">Furukawa N, Kinugasa A, Inoue F, et al. Type I glycogen storage disease with vasoconstrictive pulmonary hypertension. J Inherit Metab Dis 1990; 13:102.</a></li><li><a href=\"https://www.uptodate.com/contents/glucose-6-phosphatase-deficiency-glycogen-storage-disease-i-von-gierke-disease/abstract/64\" class=\"nounderline abstract_t\">Humbert M, Labrune P, Simonneau G. Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 2002; 161 Suppl 1:S93.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2946 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H27\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS AND CLASSIFICATION</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">GENETICS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL FEATURES</a><ul><li><a href=\"#H1052937\" id=\"outline-link-H1052937\">Metabolic hypoglycemia/lactic acidosis</a></li><li><a href=\"#H600479553\" id=\"outline-link-H600479553\">Hyperuricemia</a></li><li><a href=\"#H600479587\" id=\"outline-link-H600479587\">Hyperlipidemia</a></li><li><a href=\"#H600479663\" id=\"outline-link-H600479663\">Hematologic</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Gastrointestinal</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Endocrine</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Renal</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Neurologic</a></li><li><a href=\"#H1052957\" id=\"outline-link-H1052957\">Hepatic adenomas</a></li><li><a href=\"#H646313187\" id=\"outline-link-H646313187\">Bone density</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">DIAGNOSIS</a></li><li><a href=\"#H455049781\" id=\"outline-link-H455049781\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">MANAGEMENT</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">Prevention of hypoglycemia</a></li><li><a href=\"#H1052964\" id=\"outline-link-H1052964\">Nutrition</a></li><li><a href=\"#H600480232\" id=\"outline-link-H600480232\">Treatment of lactic acidosis</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Treatment of hyperuricemia</a></li><li><a href=\"#H600480175\" id=\"outline-link-H600480175\">Treatment of hyperlipidemia</a></li><li><a href=\"#H600480298\" id=\"outline-link-H600480298\">Neutropenia</a></li><li><a href=\"#H646313208\" id=\"outline-link-H646313208\">Anemia</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Inflammatory bowel disease</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Short stature</a></li><li><a href=\"#H646313228\" id=\"outline-link-H646313228\">Osteoporosis</a></li><li><a href=\"#H1892107488\" id=\"outline-link-H1892107488\">Renal disease</a></li><li><a href=\"#H455049813\" id=\"outline-link-H455049813\">Hepatocellular carcinoma</a></li><li><a href=\"#H1226450745\" id=\"outline-link-H1226450745\">Pulmonary hypertension</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">Liver transplantation</a></li><li><a href=\"#H1108005130\" id=\"outline-link-H1108005130\">Other (or future) therapies</a></li></ul></li><li><a href=\"#H161035966\" id=\"outline-link-H161035966\">OUTCOME</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1052820\" id=\"outline-link-H1052820\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ALLRG/2946|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/81164\" class=\"graphic graphic_figure\">- Pathways of glycogen metabolism</a></li></ul></li><li><div id=\"ALLRG/2946|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/54417\" class=\"graphic graphic_table\">- Disorders of glycogen - glucose metabolism</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-blood-pressure-percentiles-for-boys-0-to-17-years-old-revised-2017\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Blood pressure percentiles for boys 0 to 17 years old (revised 2017)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-blood-pressure-percentiles-for-girls-0-to-17-years-old-revised-2017\" title=\"calculator 2\" class=\"calc calc_professional\">Calculator: Blood pressure percentiles for girls 0 to 17 years old (revised 2017)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-body-mass-index-bmi-percentiles-for-boys-2-to-20-years\" title=\"calculator 3\" class=\"calc calc_professional\">Calculator: Body mass index (BMI) percentiles for boys (2 to 20 years)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-body-mass-index-bmi-percentiles-for-girls-2-to-20-years\" title=\"calculator 4\" class=\"calc calc_professional\">Calculator: Body mass index (BMI) percentiles for girls (2 to 20 years)</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-neutropenia\" class=\"medical medical_review\">Congenital neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dyslipidemia-in-children-management\" class=\"medical medical_review\">Dyslipidemia in children: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-environmental-factors-in-inflammatory-bowel-disease-in-children-and-adolescents\" class=\"medical medical_review\">Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-classification-and-pathogenesis-of-focal-segmental-glomerulosclerosis\" class=\"medical medical_review\">Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glycogen-branching-enzyme-deficiency-glycogen-storage-disease-iv-andersen-disease\" class=\"medical medical_review\">Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glycogen-debrancher-deficiency-glycogen-storage-disease-iii\" class=\"medical medical_review\">Glycogen debrancher deficiency (glycogen storage disease III)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertriglyceridemia\" class=\"medical medical_review\">Hypertriglyceridemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=liver-glycogen-synthase-deficiency-glycogen-storage-disease-0\" class=\"medical medical_review\">Liver glycogen synthase deficiency (glycogen storage disease 0)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=liver-phosphorylase-deficiency-glycogen-storage-disease-vi-hers-disease\" class=\"medical medical_review\">Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lysosomal-acid-alpha-glucosidase-deficiency-pompe-disease-glycogen-storage-disease-ii-acid-maltase-deficiency\" class=\"medical medical_review\">Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lysosome-associated-membrane-protein-2-deficiency-glycogen-storage-disease-iib-danon-disease\" class=\"medical medical_review\">Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=myophosphorylase-deficiency-glycogen-storage-disease-v-mcardle-disease\" class=\"medical medical_review\">Myophosphorylase deficiency (glycogen storage disease V, McArdle disease)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-inherited-disorders-of-glucose-and-glycogen-metabolism\" class=\"medical medical_review\">Overview of inherited disorders of glucose and glycogen metabolism</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-medical-management-of-high-risk-adult-patients-with-moderate-to-severe-crohn-disease\" class=\"medical medical_review\">Overview of medical management of high-risk, adult patients with moderate to severe Crohn disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-crohn-disease-in-children-and-adolescents\" class=\"medical medical_review\">Overview of the management of Crohn disease in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-medical-management-of-mild-low-risk-crohn-disease-in-adults\" class=\"medical medical_review\">Overview of the medical management of mild (low risk) Crohn disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=phosphofructokinase-deficiency-glycogen-storage-disease-vii-tarui-disease\" class=\"medical medical_review\">Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)</a></li></ul></div></div>","javascript":null}